NRG多中心临床试验中质子治疗的技术考量指南
NRG肿瘤学组织基于当前质子治疗临床试验方案,系统梳理了笔束扫描质子治疗在多中心试验中的技术挑战,包括鲁棒性评估、运动管理、自适应计划、治疗报告及数据收集局限。指南推荐直接在临床靶区上以最差情景评估计划鲁棒性,而非依赖传统光子几何外扩,并建议扩展影像与放射肿瘤学核心的数据收集以纳入束模型参数和线性能量转移信息。
要点
- 推荐直接在临床靶区上以最差情景评估质子计划鲁棒性,而非依赖传统光子几何外扩。
- 指南提供不确定度参数和最小不确定度情景集的指导。
- 建议扩展影像与放射肿瘤学核心的集中数据收集,纳入束模型参数和线性能量转移信息。
核心结论
- 该统一框架旨在提高多中心临床试验中质子治疗的实施一致性、结果可靠性和协调性,并支持未来生物剂量-效应关系研究。
研究设计与样本
- 在NRG肿瘤学组织领导下,回顾当前质子治疗临床试验方案以识别技术挑战,基于当代质子治疗实践和多中心临床试验经验制定推荐。
主要发现
- 笔束扫描质子治疗增加对摆位和射程不确定度、患者运动、分次间解剖变化及相对生物效应变异的敏感性,复杂化治疗标准化和结果解读。
关键数值与推荐
- 推荐直接在临床靶区上使用最差情景评估计划鲁棒性,而非依赖传统光子几何外扩(计划靶区)。
- 提供不确定度参数和最小不确定度情景集的指导。
- 建议扩展影像与放射肿瘤学核心的集中数据收集,纳入束模型参数和线性能量转移信息以支持独立剂量重建、交叉验证和未来回顾性放射生物学分析。
临床怎么用
- 在多中心质子治疗临床试验中,应采用基于临床靶区的最差情景鲁棒性评估替代传统计划靶区外扩。
- 应按照指南提供的不确定度参数和最小情景集进行鲁棒性评估和报告。
- 应扩展数据收集至影像与放射肿瘤学核心,纳入束模型参数和线性能量转移信息以支持独立剂量重建和交叉验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Integrating proton therapy into multi-institutional clinical trials introduces distinct physical and biological complexities. Modern pencil beam scanning enables highly conformal dose delivery but increases sensitivity to setup and range uncertainties, patient motion, interfractional anatomic changes, and variability in relative biological effectiveness. These factors complicate treatment standardization and outcome interpretation across institutions. METHODS AND MATERIALS: Under the leadership of NRG Oncology, current proton therapy clinical trial protocols were reviewed to identify technical challenges. Key issues examined included robustness evaluation, motion management, adaptive planning considerations, treatment reporting, and limitations in dosimetric and biological data collection. Recommendations were developed based on contemporary proton therapy practice and multi-institutional clinical trial experience. RESULTS: This guideline establishes a harmonized framework for proton therapy in cooperative group clinical trials and provides practical recommendations for robustness evaluation, motion management, treatment reporting, and standardized data collection. Specifically, we recommend evaluating plan robustness directly on the clinical target volume using worst-case scenarios, rather than relying on conventional photon-based geometric expansions (planning target volume). Guidance is also provided for uncertainty parameters and minimum uncertainty scenario sets. In addition, expansion of centralized data collection through the Imaging and Radiation Oncology Core is recommended to include beam model parameters and linear energy transfer information to support independent dose reconstruction, cross-validation, and future retrospective radiobiological analyses as clinical relative biological effectiveness models evolve. CONCLUSIONS: This unified framework aims to improve treatment consistency, outcome reliability, and harmonized proton therapy implementation across cooperative group clinical trials while supporting future investigation of biological dose-response relationships.
引用
- Liang X, Taylor PA, Li H, et al. Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials. Int J Radiat Oncol Biol Phys. 2026. PMID: 42150707. doi:10.1016/j.ijrobp.2026.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。